18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Recruiting now · Early Phase 1

Conditions studied: Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma, Paraganglioma

In brief

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).

Key facts

Study ID
NCT05069220
Run by
Peking Union Medical College Hospital
People needed
150
Starts
2021-09-01
Expected to finish
2026-12-01
Last updated by the study team
2024-03-01

Who can join

Age: 1 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.